Research in Brief

IF 30.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Lancet Gastroenterology & Hepatology Pub Date : 2025-02-12 DOI:10.1016/s2468-1253(25)00021-4

Holly Baker

{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(25)00021-4","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>TACE and immunotherapies for hepatocellular carcinoma</h2>Two phase 3 trials—EMERALD-1 and LEAP-012—highlight promising advances in the treatment of unresectable hepatocellular carcinoma with transarterial chemoembolisation (TACE) combined with immunotherapeutic agents.In EMERALD-1, Bruno Sangro and colleagues randomly assigned patients with unresectable hepatocellular carcinoma amenable to embolisation to receive TACE (current standard of care) plus either durvalumab plus bevacizumab (n=204), durvalumab plus placebo (n=207), or placebo alone (n=205).</section></section><section><section><h2>Thermal ablation for small colorectal liver metastases</h2>Thermal ablation is as efficacious as surgical resection for treating small colorectal liver metastases, but with fewer complications, according to the COLLISION phase 3 trial.Susan van der Lei and colleagues randomly assigned patients with ten or fewer small-size (≤3 cm) colorectal liver metastases to receive either thermal ablation (n=148) or surgical resection (n=148). The study was stopped early at a preplanned interim analysis, after a median follow-up of 28·9 months, based on a</section></section><section><section><h2>Perioperative chemotherapy for oesophageal cancer</h2>Perioperative chemotherapy improves survival in patients with resectable oesophageal adenocarcinoma, according to the ESOPEC phase 3 trial.Jens Hoeppner and colleagues randomly assigned patients to receive either perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery (n=221) or preoperative chemoradiotherapy (radiotherapy at 41·4 Gy and carboplatin and paclitaxel) plus surgery (n=217). At median follow-up of 55 months, 3-year overall survival</section></section><section><section><h2>Plozasiran for persistent chylomicronaemia</h2>The siRNA plozasiran significantly lowers triglyceride levels and reduces the risk of pancreatitis in patients with persistent chylomicronaemia, suggests the PALISADE phase 3 trial.Gerald F Watts and colleagues randomly assigned patients to receive plozasiran at 25 mg (n=26) or 50 mg (n=24), or placebo (n=25), subcutaneously every 3 months for 12 months. At 10 months, the median percentage change from baseline in fasting triglyceride level was −80% in the plozasiran 25 mg group, −78% in the</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"2 1","pages":""},"PeriodicalIF":30.9000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(25)00021-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

TACE and immunotherapies for hepatocellular carcinoma

Two phase 3 trials—EMERALD-1 and LEAP-012—highlight promising advances in the treatment of unresectable hepatocellular carcinoma with transarterial chemoembolisation (TACE) combined with immunotherapeutic agents.In EMERALD-1, Bruno Sangro and colleagues randomly assigned patients with unresectable hepatocellular carcinoma amenable to embolisation to receive TACE (current standard of care) plus either durvalumab plus bevacizumab (n=204), durvalumab plus placebo (n=207), or placebo alone (n=205).

Thermal ablation for small colorectal liver metastases

Thermal ablation is as efficacious as surgical resection for treating small colorectal liver metastases, but with fewer complications, according to the COLLISION phase 3 trial.Susan van der Lei and colleagues randomly assigned patients with ten or fewer small-size (≤3 cm) colorectal liver metastases to receive either thermal ablation (n=148) or surgical resection (n=148). The study was stopped early at a preplanned interim analysis, after a median follow-up of 28·9 months, based on a

Perioperative chemotherapy for oesophageal cancer

Perioperative chemotherapy improves survival in patients with resectable oesophageal adenocarcinoma, according to the ESOPEC phase 3 trial.Jens Hoeppner and colleagues randomly assigned patients to receive either perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery (n=221) or preoperative chemoradiotherapy (radiotherapy at 41·4 Gy and carboplatin and paclitaxel) plus surgery (n=217). At median follow-up of 55 months, 3-year overall survival

Plozasiran for persistent chylomicronaemia

The siRNA plozasiran significantly lowers triglyceride levels and reduces the risk of pancreatitis in patients with persistent chylomicronaemia, suggests the PALISADE phase 3 trial.Gerald F Watts and colleagues randomly assigned patients to receive plozasiran at 25 mg (n=26) or 50 mg (n=24), or placebo (n=25), subcutaneously every 3 months for 12 months. At 10 months, the median percentage change from baseline in fasting triglyceride level was −80% in the plozasiran 25 mg group, −78% in the

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Gastroenterology & Hepatology Medicine-Hepatology

CiteScore

50.30

自引率

1.10%

发文量

期刊介绍： The Lancet Gastroenterology & Hepatology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The Lancet Gastroenterology & Hepatology publishes papers that reflect the rich variety of ongoing clinical research in these fields, especially in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.